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Abstract 
This paper examines the profitability, liquidity and solvency and probability of failure of listed pharmaceutical 
companies on the Ghana Stock exchange. The findings from the activities ratios indicated efficiency of Arytons 
management in utilizing the asset of the firms in day-to-day basis is declining in recent years whiles that of 
Starwin is improving even though Aryton Drug Ltd is generally more efficient than Starwin Ltd. The Average 
cash conversing cycles of Aryton and Starwin were found to be 196 and 282 respectively which are relatively 
higher than the bench mark in Germany, UK and US of 145 days, 127 days and 142days respectively. The 
liquidity ratio metric indicated that Aryton Drug Ltd manages it liquidity and is very good position to meet it 
long term obligation as well, as oppose to Starwin Ltd which has very limited cash to cover its short term debt 
and is less solvent. Starwin’s is more geared which has exposed the firm to higher interest expense. The study 
also discovered from the DuPont analysis that operating income- to- revenue and revenue- to- total assets ratios 
significantly influence ROE positively. Measurement of profitability, proxy by ROE and ROA, shows that 
Aryton generates more returns on it asset and on equity than Starwin Ltd, although lower than industrial bench 
marks in UK and US of 54.9% and 32.5% respectively, however Starwin Ltd is seen to be posting good returns 
in recent years which is almost at par with Aryton’s. Starwin’s COGS growth rate has been generally greater 
than its revenue growth rate which is note the case for Aryton Ltd. A test of financial soundness and stability 
with Altman’s Z-score revealed that Aryton is not financially distress but Starwin is in financial distress and 
likely to be bankrupt in the near future, exposing investors to serious risk. Thus Starwin Ltd should consider 
takeover offer or merger for reorganization of the firm. 
 
1.1.0 Introduction 
Globally, the pharmaceutical industry offers invaluable contribution to strong economic growth in diverse ways, 
besides the main aim of production of drugs for clinical purpose or healthcare. According to (Karamehic, 2013) 
the industry generates high-quality jobs and increase economic output for economies. According to (Jhee, 2008)  
in the United States, the pharmaceutical industry is classified among the top three most profitable industries but 
in Ghana the picture is in sharp contrast, according to (Harper & Gyansah-Lutterodt, 2007). The efficiency with 
which financial decisions, with respect to source of funds and the application of the funds, are made and other 
production inputs affects profitability. Theoretically, every management is required to optimize firm available 
resources, to maximize shareholders wealth, failure of which will results in low returns on equity.  
Thus elsewhere some attention has been focused on the financial performance of the Pharmaceutical 
industry to provide much insight into their annual reports; United States, (Goodman, 2009) and in India (Nair, 
2013)and (Kheradmand & Bahar, 2013), but very little is known about the financial performance of the industry. 
The absence of critical financial indicators about the performance firms in the sector affect attractiveness of 
investments and trading volumes and value of financial assets holdings of investors in the sector. Thus the 
purpose of this study is to examine the profitability, liquidity and solvency of the publicly traded Pharmaceutical 
companies on Ghana stock exchange and also identify financial ratios with significant contribution effects on 
return on equity and further test the financial soundness or distress of the firms.  
This study employs multi-method; trend and DuPont, regression analysis as well as Altman Z-score and 
to examine firms’ financial data from 2006 to 2012. In spite of the limited number of pharmaceutical companies 
studied and the lack of industrial averages for relative performance or comparative analysis, this paper reveals 
critical findings about the performance of the selected companies for which are of immense to benefit to the 
industry’s regulators, investors, academics and other relevant stakeholders. 
The findings are expected drive the necessary policy changes to attract the needed investment in the 
industry and to improve their competitive position of the firms in the global and domestic marketplace.  
The rest of the paper is organized as follows: Chapter two gives literature review about the study. 
Chapter Two reviews the existing literature. Chapter three entails the methodology applied to achieve the 
objectives of the study. The data analysis, findings and discussion are presented in Chapter four. In Chapter five, 
the Summary, conclusions and recommendations are presented. 
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Overview of pharmaceutical industry in Ghana 
 Ghana’s pharmaceutical manufacturing sector is rated the best in West Africa for producing high quality 
pharmaceuticals as result of stringent regulation. About 30% of the Pharmaceuticals in Ghanaian market are 
locally produce and whiles about 70% are foreign mainly from India and China, (PMAG, 2012).There are about 
38 registered manufacturing firms currently.  About 29 of the firms belong to local industrialists, of which just 
Starwin and Aryton are listed on the Ghana Stock Exchange currently.  
Both (Harper & Gyansah-Lutterodt, 2007) and (PMAG, 2012) reported that the sector is bedevil with 
access to long term finance, development capital  and high financing cost, distribution and importation of 
relatively cheaper drugs from China and India, hence they produce under capacity of about 55% on the average.  
Financial performance of the industry globally: key developments 
This part looks at various empirical works and reports of the financial performance of the industry elsewhere and 
drug development cost.  
The industry’s value added process is characterized by high capital expenditure and higher returns, 
though with startling higher risks. According to (Ogbru, 2009) the sector requires huge capital investment in 
billions of dollars medicinal compounds discovery, however only infinitesimal part of about 0.01% successfully 
realize as authorized drug. Studies conducted by (PhRMA, 2012) in United Stated affirmed the high risk involve 
in pharmaceutical production as they found that the average cost to develop a drug, including the cost of failures 
is $1.2 billion and it takes about 10 to 15 years to develop a drug of which only 15% approved drugs generate 
sufficient revenue to compensate for the costs of their development. In addition, only 33% of every approved 
drug brings in adequate sales to offset the costs of development of previous unsuccessful or rejected compounds.  
In the United States, (Goodman, 2009) found that the U.S pharmaceutical industry growth rate plummeted to 6.7% 
from 2004 to 2009.  (Bashar & Islam, 2014) studied into factors that influence the industry’s profitability in 
Bangladesh and found among other  ratios the Average Inventory/Cost of Goods Sold and  Average Accounts 
Payable/Cost of Goods Sold significantly influenced  the gross profit margins of the firm. (Leahy, 2012) had 
similar findings in terms Average Inventory/Cost of Goods but in addition found average accounts receivable / 
net sales as a key determinant of profitability but surprising found average accounts payable/cost of goods 
insignificant as ratio, indicating rising short term liabilities thus not significantly affects profitability of U.S 
pharmaceutical manufacturers. In India (Ashvin, 2012) found that total assets to sales ratio and creditors’ 
velocity were critical to the achievement of optimum profit for some selected pharmaceutical companies. 
Also in study conducted by (Nair, 2013) on the Indian pharmaceutical companies’ financial 
performance, found that 48 % of the companies were likely to be financially distress and 9% of the companies 
were financially distressed due to decreased EBIT. Recently (Karamehic, 2013) also analysed the financial 
performance of the United States Pharmaceutical industry and forecasted that the industry’s profits were likely 
going to decline in the future.     
Financial performance metrics 
Predominantly accounting ratios are used to gauge financial performance of firms and there exist a plethora of 
them. For instance (Gombola & Ketz, 1983) identified 58 financial ratios, with varying structure from one 
industry whiles (Ho & Wu, 2006) identified 59 ratios. However, various financial literatures such as (CFA, 2012)  
broadly categorized them into Asset utilization (Activity), Liquidity, Solvency, Profitability and shareholders 
ratio to measure specific financial or financial characteristics of business. Empirical studies by (Bhunia & Sarkar, 
2011) found financial ratios could forecast the Bankruptcy of Indian pharmaceutical firms. 
 
2.1 Methodology 
The study was conducted by selecting the annual financial statements and reports from the period between 2005 
and 2012 of the listed pharmaceutical companies on the Ghana Stock Exchange.   
 Trend, common size ratio and percentage change analysis were employed.  
For purpose of logical analysis and interpretation they were classify into Activity, Liquidity, Solvency, 
Profitability and Investor ratios. In calculating the solvency ratios only interest-bearing short debt term and long 
debt were used. Also regression analysis was employed to find critical factors that affect each company’s overall 
profitability proxy by Return on Equity from DuPont Five-factors. 
Finally, Altman’s z-score model was also used to identify whether any of the selected companies faces 
eminent financial distress.  
The Z-score bankruptcy predictor combines five common business ratios, using a weighting system that 
was statistically calculated by Edward Altman to determine the likelihood of a company going bankrupt at some 
point in the future. 
ALTMAN’S Z-SCORE BANKRUPTCY PREDICTION MODEL 
  3.3  0.999
  0.6  1.2  1.4, 
 Where; 
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,   x2=
Sales
Total assets
,   x3=
Equity
Debt
,   x4=
Working capital
Total assets




This model of Altman’s Z-score was chosen because all the companies are public companies and considers only 
financial factors only.  
 
3.1.0   Results and discussion 
 This section shows the results of the data analysis used in achieving the research objectives. 
Table 1    Financial ratios for Aryton drug manufacturing company limited 
RATIOS 2012 2011 2010 2009 2008 2007 2006 Average 
Liquidity 
Current ratios 6.9424 6.6329 6.11373 9.80646 6.5881 6.36675 4.84222 6.75608 
Quick ratios 4.02151 4.40049 4.09743 6.22863 2.56676 3.95528 3.33157 4.08596 
         Efficiency 
Inventory turnover 2.33259 2.6751 1.87267 2.28811 2.17523 2.90712 5.70851 2.85133 
Days sales in inventory 156.478 136.443 194.909 159.52 167.798 125.554 63.9397 143.52 
Days sales in receivable 119.589 110.675 136.173 76.7758 71.7542 84.2769 46.2261 92.21 
Total assets turnover 1.11972 1.11713 0.85361 1.33885 1.23723 1.16235 2.11497 1.2777 
         Solvency 
Debt-to-equity 0.1253 0.14259 0.13341 0.08381 0.12064 0.12444 0.15241 0.12609 
Long Term Debt-to Asset 0.0034 0.01297 0 0 0 0 0 0.00234 
Profitability 
Return of assets 0.12056 0.15967 0.15925 0.24575 0.18443 0.18092 0.27485 0.18935 
Return on equity 0.13665 0.18176 0.17697 0.27035 0.207 0.20841 0.32592 0.21529 
Net Profit (%) 0.10767 0.14293 0.18656 0.18355 0.14907 0.15565 0.12995 0.15077 
          
Table 2 :     Financial ratios for Starwin products limited. 
RATIOS 2012 2011 2010 2009 2008 2007 2006 Average 
Liquidity         
Current  1.54963 1.53547 1.46875 1.08392 1.41772 1.50906 1.72956 1.47059 
Quick  0.63525 0.93322 0.51434 0.48579 0.64646 0.66705 0.76335 0.66364 
         Efficiency         
Inventory turnover 1.76728 1.58793 1.45097 1.62858 1.49052 1.14356 1.14046 1.45847 
Days Sales in inventory 206.532 229.858 251.557 224.122 244.881 319.179 320.046 256.597 
         Days in sales receivable 89.7385 81.9371 59.9258 69.918 88.5832 99.8314 128.328 88.3231 
Total assets turnover 1.17573 1.13634 1.00567 0.87172 0.73815 0.62926 0.69608 0.89328 
         Solvency         
         Debt-to-equity 0.74792 0.59042 1.00372 1.09505 0.72234 0.61543 0.44246 0.74533 
Long term debt 0.01026 0.00914 0.10733 0.02517 0.09804 0.0845 0.03961 0.05344 
Times interest earned 3.8651 3.71733 1.39167 0.48781 0.31177 0.73134 9.80707 2.90173 
         Profitability          
Return on assets 0.07317 0.12772 0.02221 -0.0436 -0.0395 0.00829 0.03194 0.02574 
Return on equity 0.12279 0.22694 0.04558 -0.0831 -0.0660 0.01284 0.04134 0.0429 
Net Profit (%) 0.06223 0.1124 0.02209 -0.0501 -0.0536 0.01318 0.04588 0.02174 
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Graphical presentation, analysis and findings 
 
Fig. 1 Revenue and COGS and Net income growth rate 
 
The figure 1 above shows the growth rate in revenue, cost of goods sold (COGS) and net income of Aryton Ltd. 
In 2007 and 2008 it appears the growth rate in revenue and COGS were approximately equal at 18.1% in 2007 
and 25% in 2008, whiles the net income growth rate move from 42.8 to 20.2% in these years. The net income 
growth rate jumped to 60.5% in 2009 but plummeted together with the revenue and COGS rate to -18.4%. In 
2011 revenue and COGS rate rose simultaneously even though COGS rate was higher than growth in revenue. 
The variation in the rate of growth of the variables seems to be huge. The average (geometric) growth rate in 
revenue, COGS and net income are respectively 19.4%, 17.9% and 15.7%. 
 
Fig. 2 Revenue and COGS of Starwin Ltd 
 
The figure 2 above shows the growth rate in revenue, cost of goods sold (COGS) and net income of Starwin Ltd. 
With the exception of 2010 and 2011 the company’s growth rate in COGS were higher than the growth rate in 
sales but generally at declining rate up to 2011. Between 2009 and 2011 there was huge drop in rate of COGS 
from 27.3% to -3.5% and jump to 26.4% above the revenue growth of 13.6% in 2012. The figure shows that 
Starwin’s COGS growth was on the average higher than its revenue growth rate. The Geometric growth rate in 
revenue and COGS were approximately 16.5% and 20.2% whiles the average net income growth was -0.60.5%. 
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Figure 3 shows the trend of the cash conversion ratio for both firms. It indicates the number of days taken for 
Starwin averagely to convert it raw materials to cash is relatively higher than that of Aryton Ltd. For the seven 
year period the average cash conversion cycle for starwin and Aryton is approximately 282 days   with negative 
skewness   and 196 days with higher negative skewness respectively. However, Starwin’s cash conversion cycle 
has improved significantly in recent years by trending downwards, a sharp contrast to Aryton, this is observed in 




The fugure 4 above indicates that the cash ratio of Aryton is far better than that of Starwin. The cash ratio of 
Aryton declined from its maximum value of 1.6  to 0.5 from the period between 2006 and 2008 whiles rising 
thereon to approximately 1.5 in 2010 then trended downwards again thereafter. On the average the ability of 
Aryton to meet its current liabilities with cash and near cash equivalent is far better than Starwin. On the average 
Aryton’s cash has been 1.1 times their current liability over the seven year period with variability of 0.43, whiles 
that of Starwin is approximately 0.28 with a variability of 0.91. However, the current asset to current liabilities 
of Starwin on the average over the years has been 1.5 as shown in the figure below.  Thus for every ₵1 current 
liabilities incurred, it has ₵1.5 current asset to pay it on the average with a deviation of 0.2. It therefore suffices 
to conclude that Aryton Ltd is more liquid than Starwin. 
 
Fig. 5-Current ratio 
 
Figure 5 shows the current ratio for Aryton Ltd  and Starwin Ltd . It indicates that Aryton’s current ratio was 
4.84 for 2006, increased to 6.36 in 2007 and 6.58 2008.There was a high percentage change of about 48% 
between 2008 and 2009 as the figure soared to 9.8 in 2009. The figure decreased to 6.11 in 2010, moved a little 
up 6.63 in 2011 and 6.94 for the year 2012. This implies that the current assets of Aryton were able to cover its 
current liabilities up to an average of about 6.76 times over the seven year period.  With the period the change in 
Aryton’s cash ratio with respect to time remained positive. As such the company has been able to meet its short 
term debt obligations.  
The figure 3 however shows that the Current ratio for Starwin Products Limited remained relatively low 
trending with a negative rate of change within the period.  
 This implies that the current assets of Starwin Products Limited were able to cover its current liabilities 
up to an average of about 1.47 times over the seven year period whiles Aryton's current ratio could cover its 
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Fig.6-Debt to Equity ratio 
 
The figure 6 above shows the Debt to equity ratio of the two companies. It indicates that Starwin gear ratio has 
been higher than that of Aryton. The average percentage with regard to debt of equity is 74.53% with skewness 
of 0.49 and 12.61% with skewness of -1.19 for Starwin Ltd and Aryton Ltd respectively. Between 2006 and 
2009 Aryton debt to equity ratios were reducing marginally. The rate of decrease within the period remained 
approximately constant at -12%.   It got the minimum value of 0.084 whiles within the same period Starwin gear 
ratio increased sharply from 0.44 to a maximum value of 1.01. However after 2009 it declined continuously to 
approximately 0.59 in 2011 but changed it trajectory there on. It depicts trending up with increasing rate of 
change in Starwin’s Debt to Equity ratio. This implies Starwins solvency has being weakening over the period 




The figure 7 shows the trajectory of the reliance of debt financing by the firms. It shows that Starwins Ltd relied 
on more debt finance than Aryton. Whiles Starwin total asset to equity ratio kept increasing at an approximately 
constant rate of (0.189) 19% with the time period between 2006 to 2010 Aryton’s leverage change it with respect 
to time remained approximately zero by maintaining approximately constant leverage ratio of 1.11. This 
indicates that about 90% of the total assets of Aryton is financed by equity and thus for ₵1.11 value of asset 
acquired by Aryton  ₵1.00 from shareholders’ fund is used to financed it. In the case of Starwin the average 
leverage ratio remains relatively higher at 1.7. In 2010, it reached maximum ratio of 2.1 and declined to 1.68. 
Thus on the average for every ₵1.70 assets of Starwin ₵1.00 is from equity. Conclusion:  Clearly Starwin is 
highly leveraged than Aryton Ltd. 
 
Fig. 8- Return on Assets 
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Figure 8 shows that return on assets of Aryton was persistently higher than Starwin, though generally at decline 
rate as the trend point downwards. The average rate of change was approximately -1.9% with an average of 
about 18.94%. As shown the maximum and the minimum occurred in the year 2006 and 2012 respectively.  
Starwin’s return on assets remained relatively low, going to negative in 2008 and 2009. However, from the 2010 
up to 2012 Starwin improve on their performance with positive returns on assets. For the seven year period under 
considerations Aryton could make an average return of each cedi of asset of about ₵0.19 as opposed to Starwin's 
average return on assets of  ₵ 0.03. 
 
Fig.9-Return on Equity 
 
The figure 9 above shows the graph of return on equity for the firms. Similarly, as in the case of return on asset, 
Aryton’s return on equity remained higher than that of Starwin in the period between 2006 and 2010 but it shows 
decreasing rate as shown by the trend line. Aryton recorded its highest value in 2006 and minimum value in 
2012. In the years 2007, 2008 and 2011 it remained relatively constant at about 0.20. Although Starwin’s return 
on equity was relatively lower in the years between 2006 and 2010, Starwin show up sharp increase in 
performance from 2009 peaking in 2011 at about 0.23 and both companies posting about the same results 
approximately 0.13 returns on asset. The average return on equity for Aryton was approximately 22% whiles that 
of Starwin was approximately 4.3%.  
 
3.1.1 DUPONT ANALYSIS. 
The figure 10 below shows the decomposition of the ROE in it expanded form to identify key profitability 
factors or ratios. The figure indicates that factors that greatly affect the profitability of Aryton measured in terms 
of returns on equity are revenue to asset ratio and earnings before taxes to operating income. From  2006 to 2007 
a drop in value of the revenue to asset ratio also saw the ROE fell from approximately 0.32 to 0.21 and when the 
revenue to asset ratio increased from 1.16 to 1.34 in 2007 to 2009 the ROE of Aryton increased marginally from 
0.208 to 0.27. Overall it seems there exists positive correlation between them and a change in revenue to asset 
ratio with respect to change in ROE is positive. Although, variations in the earnings before taxes to operating 
income ratio of Aryton over the years seems not be huge but from the graph it positively correlates with the 
company’s ROE. For instance from the period between 2007 to 2009 when the it increased from approximately 
0.15 to 0.18, the ROE moved from approximately 0.21 to 0.27. Thus a percentage   change of about 18.9%  of 
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Figure 10 -decomposition of the ROE 
 
3.1.2 Regression analysis of the Dupont factors. 
The regression analysis that was done on the components to critically examine which of them has significant 
impact on the ROE is shown below. 
Table 3: The Regression Results of DuPont Analysis 
  Coefficients Standard Error t Stat P-value 
Intercept 0.378712 0.262282 1.443913 0.385611 
TA/EQ 0.026264 0.081838 0.320925 0.802303 
RE/TA 0.141078 0.008155 17.29916 0.03676 
OP.INC/REV 1.315858 0.06589 19.97048 0.031851 
EBT/OP.INC -0.11116 0.060236 -1.84542 0.316139 
1-(TA/EBT) -0.53025 0.203713 -2.60293 0.23351 
 
Base on the P-values above the components with significant impact on the ROE are operating income to 
revenue and revenue to total assets ratios at 5% and that they all have positive relationship with ROE. Keeping 
all ratios constant 1% increase in revenue to total assets leads to about 0.14% increase in ROE and 1% increase 
in operating income to revenue could results 1.32% increase in ROE. 
 
 
The Z-score Analysis:Using the Altman’s Z score model it was found out that Aryton drugs manufacturing 
limited is operating in safe financial conditions since its Z score over the period under study has been above the 
minimum safe zone score of 2.99. For Starwin, the company has been struggling financially and was in financial 
distress and was likely to go bankrupt between 2008 and 2010 since its Z score for the preceding two years was 
below the safe zone.  The company was in serious financial distress in 2008 and 2010, but management were 
able to put in measures to make the company profitable and also got some short term finances in the form of 
overdraft to sustain the company. From the 2012 figure of 2.6 still the company is likely to be bankrupt in the 
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4.1.0 Major findings   
4.1.1Activity management performance. 
The cash conversion cycle of Aryton is on the average shorter than Starwin but starwin is doing better in recent 
years in converting it raw materials quicker than Aryton. Thus the efficiency of Arytons management in utilizing 
the asset of the firms in day-to-day basis is found to be dropping whiles that of Starwin is improving. However, 
the Average cash converting cycles of both Aryton and Starwin of 196 and 282 respectively are relatively higher 
than the bench mark in Germany, UK and US of 145 days, 127 days and 142days respectively. 
4.1.2 Liquidity management 
Over all it is found that Aryton Ltd maintains enough liquid asset to meet it short term liabilities than Starwins 
Ltd as they fall due over the period of study, hence Aryton is more liquid than Starwin even though the cash ratio 
is seen to be declining in recent times whiles the current ratio is relatively increasing from the year 2010. 
Comparatively, Aryton Ltd maintains cash ratio equivalent to the bench marks in Germany ( 2.3), UK (0.9) and 
US (1.1) . Aryton’s average cash ratio is found to be 1.1 with the standard deviation of 0.43. Starwins Ltd cash 
ratio of 0.28 averagely is below the bench marks of its local and global competitors, hence it emerges that it has 
not being maintaining enough cash to meet the current financial claims on the company. 
4.1.3 Solvency performance measurement 
The two metrics, debt- to- equity and asset- to- equity ratios, used to measure the relative solvency revealed that 
Starwin is more geared than Aryton.  Starwin employs more debt to finance it activities than Aryton, which 
implies that it makes more interest expense than Aryton. Investment in Starwin is seen to be more risky than 
Aryton as it is more vulnerable to downturns in the business cycle since the company must continue to service its 
debt regardless of lower sales volume. On the average, for every ₵1.00 of shareholders fund employed by 
Aryton Ltd, it supports it with 12 pesewas debt whiles for Starwin for every ₵1.00 equity employed it supports it 
approximately 75 pesewas  lender’s fund on the average sometimes borrowing more than 100% of equity. Thus 
Aryton is more solvent than Starwin. 
4.1.4 Profitabilty performance 
Measurement of profitability, proxy by ROE and ROA, shows that Aryton has being generating more returns on 
it asset and on equity than Starwin, however Starwin is seen to be posting good returns in recent years, starting 
from 2011 than before and almost at par with Aryton’s. For every one cedis equity employed both generated 
18.2% in 2011 and 13.7% returns on equity compare to industrial bench marks in UK and US of 54.9% and 32.5% 
respectively. The performance of Aryton is observed to be falling since 2006 when the firm met the bench mark 
in US. Also Aryton Drug Ltd is a more profitable than Starwin as it makes an avrege net profit of ₵ 0.15 on 
every ₵ 1.00 sale made as compared to Starwins average, of ₵ 0.02 on every ₵ 1.00 sales made.  
The DuPont analysis revealed that operating income- to- revenue and revenue- to- total assets ratios 
significantly influence ROE positively. Analysis of COGS and revenue shows that Starwin Ltd is not minimizing 
it cost of goods sold to make the firm more profitable compare to Aryton Ltd. Starwins COGS growth rate has 
been generally greater than its revenue growth rate which is note the case for Aryton Ltd. 
4.1.5 Test of financial distress Or bankruptcy 
Applying Altman’s Z-score to investigate the likelihood of the firms going into bankruptcy, it is found out that 
Aryton Ltd  Z-score has being higher, way above the bankruptcy range, indicating Aryton Ltd is financially 
sound and no near financial distress. However, the Z-score of Starwin Ltd has being within bankrupt zone of 1.8 
to 2.7 score except in 2011where it went up into the grey area. Over all Starwin is not financially sound and has 
being operating in a situation of financial distress and being struggling to survive. 
 
5.1.1 Conclusion and recommendation 
In summary the study has shown that the management of Aryton drug manufacturing limited are more efficient 
in managing the activities of the firm but Starwin Ltd has been ineffecient though there has improving in recent 
years.  In terms of Liquidity, Aryton is more liquid than Starwin as it has an average cash ratio of 1.1 to cover its 
short term liabilities as opposed to Starwin’s 0.28 averages meaning it is unable to cover its short term debt. 
Starwin Ltd is found to be more geared as it employs more debt to finance its operations than Aryton. 
As such Starwin Ltd makes a lot of interest expense and is expose to higher risk in economic down turn than 
Aryton.  Investing in Starwin is very risky than investing in Aryton. Aryton is solvent than Starwin. 
The study also found that Aryton Ltd is more profitable than Starwin as it makes a net profit of ₵ 0.15 
on every ₵ 1.00 sale made as compared to Starwins Ltd’s average, of ₵ 0.02 on every ₵ 1.00 sales made. 
Starwin’s COGS growth rate has been generally greater than its revenue growth rate which is note the case for 
Aryton Ltd. Starwin’s Ltd Geometric growth rate in revenue and COGS were found to approximately 16.5% and 
20.2% whiles the average net income growth was -0.60.5%. whiles Aryton’s Ltd average (geometric) growth 
rate in revenue, COGS and net income were respectively 19.4%, 17.9%  and 15.7%. A test of financial 
soundness and stability with Altman’s Z-score revealed that Aryton is not financially distress but Starwin is in 
financial distress and likely to be bankrupt in the near future, exposing investors to serious risk. Thus Starwin 
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Ltd should consider takeover offer or merger for reorganization of the firm whiles investors have cautious 
investing Starwins Ltd. 
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